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Abstract: Conventional interferons including interferon-α (IFN-α) are cytokines used for 
years in the treatment of solid tumors and hematological malignancies. Their half-life is short. 
Pegylated forms of IFN-α present an improved pharmacokinetic proﬁ  le that rendered them the 
preferred IFNs in hepatitis therapy. In the last decade, pegylated interferons (PegIFNs) have 
been investigated in melanoma patients. We review the scientiﬁ  c published literature on biology, 
pharmacokinetics, side effects and clinical applications of PegIFN-α in the treatment of stage 
III and IV melanoma. In the adjuvant setting, PegIFNα-2b has signiﬁ  cant prolonged distant 
metastases free survival in patients with microscopic nodal involvement (stage TxN1aM0) and 
therefore is a promising treatment option in this patient population. In the palliative setting, 
monotherapy with PegIFNα-2α can induce complete remissions in a minority of stage IV 
melanoma patients. The combination of monochemotherapy is feasible and may result in lasting 
complete remissions. Ongoing research must focus on the identiﬁ  cation of patients who mostly 
beneﬁ  t, so that unnecessary toxicity would be avoided. Combining PegIFNs and chemotherapy 
or targeted agents deserves further exploration.
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Introduction
Interferons (IFNs) type I and II and their receptors
Since the discovery of IFNs by Isaacs and Lindemann in 1957,1 when they were 
originally described as agents that interfere with inﬂ  uenza virus replication, a 
tremendous number of studies using predominantly type I IFNs have been conducted. 
Only in 1978 was IFN puriﬁ  ed in amounts that allowed physical and chemical char-
acterization.
IFNs are pleiotropic cytokines. They inhibit viral replication within host-cells 
through the induction of proteins and activation of speciﬁ  c signaling pathways.2–6 
Among IFN-induced proteins that affect virus replication is protein kinase R (PKR) 
which is activated by dsRNA (actually by 2’,5’ oligoadenylate synthetase, 2,5 OAS). 
After activation, PKR phosphorylates another protein, the eukaryotic translation 
initiation factor, eIF2. This factor has reduced ability to initiate translation. Other 
proteins identified, are the group of Mx proteins, RNase-L nuclease and the 
RNA-speciﬁ  c adenosine deaminase (ADAR). The ability of IFNs to upregulate major 
histocompatibility complex 1 (MHC) may also contribute to antiviral response.
IFNs interfere with immune functions by activating natural killer (NK) cells and 
macrophages, though they protect the unaffected cells from NK cell-mediated lysis,7 
and they augment antigen presentation to lymphocytes. These activities explain their 
implications in autoimmunity.
The central role of plasmacytoid dendritic cells (pDCs) to innate antiviral response 
system by producing type I IFNs has been documented.8,9 They regulate and link the 
adaptive and innate immune response.10,11 Human pDCs induce also the production Biologics: Targets & Therapy 2009:3 170
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of IFN-γ in NK cells through interleukin-2 (IL-2) secretion. 
They express a subset of toll-like-receptors (TLRs), including 
TLR-7 and TLR-9, which allow them to detect presence of 
DNA and RNA viruses.12 Furthermore, it has been demon-
strated that pDCs inﬁ  ltrate solid tumors.13,14 This observation 
posed intriguing questions about their potency in antitumor 
response. Recently it has been shown that pDCs are them-
selves capable of inducing antitumor immunity by activating 
NK and T cells.15
In addition to their antiviral and immunomodulatory 
effects, IFNs are considered to be antiangiogenic.4,16
Recently, the involvement of both IFN type I and II 
in the elimination phase of cancer immunoediting has 
been identified.17,18 IFN-unresponsive hosts show an 
increased tumor incidence and the tumors that arise in 
IFN-unresponsive environments are highly antigenic.
Although ﬁ  rst approval was for hairy cell leukemia and 
for Kaposi sarcoma19 they are widely used as a ﬁ  rst line 
therapy in the treatment of many diseases such as chronic 
hepatitis C and B, multiple sclerosis (IFN-β) and melanoma 
(IFN-α). Despite the fact that their efﬁ  cacy has been also 
demonstrated in other diseases such as follicular non 
Hodgkin’s lymphoma, condylomata acuminata, basal cell 
carcinoma, chronic phase Philadelphia (PH) chromosome-
positive chronic myelogenous leukemia (CML) and renal 
cell carcinoma20–24 they are not regularly used as a ﬁ  rst line 
treatment in these malignancies.
Types of IFNs
IFNs belong to the large class of glycoproteins known as 
cytokines. In 1980s IFNs were simply classiﬁ  ed in 3 groups: 
IFN alpha (α), IFN beta (β) and IFN gamma (γ).25 This 
categorization was based on antigenic speciﬁ  city. Today, 
they are classiﬁ  ed according their structural and functional 
properties in IFN type I, IFN type II and IFN-like 
cytokines.
Type I IFNs
There are 13 IFN-α (α-1, α-2, α-4, α-5, α-6, α-7, α-8, 
α-10, α-13, α-14, α-16, α-17, α-21)26 members and a single 
member of each IFN-β, IFN-ε, IFN-κ IFN-ω, IFN-δ and 
IFN-τ.27–29 The genes encoding all members of IFN type I 
family are situated on chromosome 9.30
IFNs type I are generally acid stable. IFN-α consists 
of 165 to166 amino acids, 5 α helices which link to a 
loop (Ab) and 3 shorter segments.31 IFN-α1 and IFN-2α 
are approximately 80% homologous but differ overall by 
29 amino acids.32,33 Although all type I IFNs are secreted in 
low amounts by all cell types, IFN-α is produced by white 
blood cells other than lymphocytes.
The molecular structure of the two recombinant IFNs-2α 
(IFNα-2α and IFN-α2b) differs from one another only by one 
single amino-acid at position 23.34 IFNα-2α and IFN-α2b 
show the same efﬁ  cacy in the treatment of chronic hepatitis C, 
hairy cell leukemia and Kaposi’s sarcoma.
IFN-β is a member of type I IFN which consists of 
166 amino acids;28 it is produced by ﬁ  broblasts and it is 
metabolized in the liver. IFN-β is used nowadays for the 
treatment of multiple scleroses (MS). Two forms of IFN-β 
are used therapeutically.
These forms of IFN-β can be produced either in bacterial 
expression systems (IFNβ-1b) or in mammalian cells 
(IFNβ-1α). They have shown some difference in their struc-
ture but their transcriptional response seems to be similar. 
There is also a difference in their biological response, with 
the IFNβ-1α molecule showing a greater biological potency 
in its antiviral activity35 than IFNβ-1b. It has been shown that 
IFNβ-1α has an additional beneﬁ  t of slowing or preventing 
the development of MS-related brain atrophy.36
All type I IFNs exert their biologic activities by binding 
to a speciﬁ  c cell surface receptor complex, known as the 
IFN-α receptor (IFNα-R). IFN-α receptor is the same for 
all members of type I IFN family. It consists of a subunit of 
a 135 kDa IFNα-R1 and of a subunit of 115 kDa INFα-R2 
chains. Both receptors are located on chromosome 9.32,37 
The primary signaling pathway activated by IFNs is the 
Jak-Stat pathway.38–40 The IFNα-R1 and IFNα-R2 receptors 
bind to Janus-activated kinase (Jak) molecules, Tyk2 and 
Jak1 respectively.41–43 Upon binding to its receptors, the 
receptor undergoes oligomerization, with transphosphory-
lation of Jaks followed by phosphorylation of the receptor 
molecule. This leads to activation of signal transducers and 
activators of transcription (Stats), Stats 1 and Stats 2, which 
are phosphorylated by the Jaks. The phosphorylated Stats 
translocate to the nucleus and activate the transcription of 
IFN – stimulated genes (ISGs). IFN stimulated gene factor 3 
(ISGF3) is an important transcription factor which is induced 
by type I IFNs.44
Although IFN-α and IFN-β predominantly signal through 
Stat-1 and 2,45 their pathway can involve Stat-3, Stat- 5, Stat-4 
and Stat-6.42,46–52 Stat 1 plays a prominent role in immune 
response, while Stat-3 is implicated in tumor progression. 
Stat 4 and Stat 6 are activated in certain cells, such as 
endothelial cells and lymphoid cells.50,52
Except Jak-Stat other pathways activated by IFNs have 
been recognized. Of the various mitogen-activated protein Biologics: Targets & Therapy 2009:3 171
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kinase (MAPK) pathways, p38 signaling has the most 
important role in the generation of IFN-mediated signals.53–55 
Other pathways include the phosphatidyl-inositol 3-kinase 
(PI3K) signaling pathway 56 and the CRK family of adaptor 
proteins.57 Nevertheless it is now understood that no signaling 
activation cascade alone is sufﬁ  cient for the generation of IFN’s 
biological properties. Cooperative function of this network of 
cytokines is needed for IFN-mediated immune response.
Another member of type I IFN family, IFN-κ, consists 
of 207 amino acids, including an amino acid peptide and a 
series of cysteines conserved in type I IFN. Expression of 
IFN-κ is signiﬁ  cantly enhanced in keratinocytes upon viral 
infection, upon exposure to double-stranded RNA, or upon 
treatment with either IFN-β or IFN-γ.36
Of the other members of type I IFN family, IFN-δ is 
not found in humans and IFN-τ is found only in ruminant 
ungulate species.58,59 Human IFN-ε appears to play a role in 
reproductive function in placental mammals.60 Finally IFN-ω 
consists of 172 amino acids, displays 60% similarity to IFN-α 
and is also produced by leukocytes.28
Type II IFNs
There is only one member of this class of IFNs, IFN-γ.27,31 
It is pharmacologically and chemically distinct from type 
I IFN. IFN-γ is a dimerized cytokine produced by NK and 
T cells located on human chromosome 12.
IFN-γ monomer consists of 140 amino acids and of a core 
of six-helices with an extended sequence in the C-terminal 
region.61
In contrast to IFN-α and IFN-β which can be expressed 
by all cells, IFN-γ can be expressed by T-helpers 1 cells 
(Th1), Tc cells, NK cells, professional antigen-presenting 
cells (APCs), B cells and natural killers T cells (NKT).62–65 
IFN-γ is known to enhance neutrophil phagocytosis and 
microbicidal activity, to induce the expression of fragment 
crystallizable (Fc) receptor for immunoglobulin G (IgG) 
and to exert anti-apoptotic effect on human neutrophils.66 Its 
antitumor, antiviral and immunoregulatory effects have been 
recognized.67 It alters transcription of more than 30 genes 
with pleiotropic functions.
IFN-γ is structurally different from type I IFN, binds to a 
different receptor and is encoded in a different chromosome. 
Two receptors have been recognized for IFN-γ: IFNγ-R1 and 
IFNγ-R2. These receptors are associated with Jak 1 and Jak 2, 
respectively.41,68 The most important transcription factor of 
IFN-γ is Stat-1.46,47,69,70 Stat-1 translocates to nucleus and 
binds IFN-γ activated sequence (GAS) elements to initiate 
transcription.46,47,69,70 IFN-γ does not induce the formation of 
ISGF3 complexes such as type I IFNs.
IFN-γ is approved by the US Food and Drug Adminis-
tration (FDA) for use in chronic granulomatous disease. In 
Japan IFN-γ was registered for cutaneous T-cell lymphoma 
in 1997.71
In conclusion, type I, predominantly IFN-α and IFN-β, 
and type II IFNs may signal through distinct pathways and 
speciﬁ  c cell surface receptors, but exhibit partly overlapping 
biologic effects particularly through their anti-proliferative 
activities.69
IFN-λ
Another group of cytokines, consisting of IL-28 and IL-29, 
was recognized as a third class of IFNs which are produced 
by lymphocytes. The genes encoding this family of cytokines 
are clustered on human chromosome 19. The group con-
sists of three members: IFNλ1, IFNλ2 and IFNλ3. The 
group expresses its activity by signaling through a receptor 
complex consisting of IL10R2 (also designated as CRF2–4) 
and IFNλ-R1 (also designated as CRF2–12).30
Pharmacokinetics of IFN-α
IFN-α are suitable for intravenous (iv), intramuscular (im) 
and subcutaneous (sc) administration. They are not absorbed 
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Figure 1 Signaling pathways activated during engagement of the type I IFN receptor. 
IFNα-R1 and IFNα-R2 bind to Tyk2 and Jak1 respectively.   After the phosphorylation 
of the receptor molecule, signal transducers and activators of transcription (Stats) 
are activated.Biologics: Targets & Therapy 2009:3 172
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orally, since they are degraded in the gastrointestinal tract.72 
IFN-α undergo proteolytic degradation during renal tubular 
re-absorption causing a negligible amount to remain in 
systemic circulation.
After a 36 million international units (MIU) iv infusion 
of recombinant IFNα-2α (rIFNα-2α) (Roferon®) in healthy 
people, an elimination half-life of 3.7 to 8.5 hours (mean 
5.1 hours), volume of distribution at steady-state of 0.223 to 
0.748 L/kg (mean 0.4 L/kg) and a total body clearance of 2.14 
to 3.62 mL/min/kg (mean 2.79 mL/min/kg) was exhibited.72
There was no significant difference between the 
pharmacokinetics of rIFNα-2α after single im dose in 
patients with disseminated cancer and healthy volunteers.72
There were no changes in the distribution or elimination 
of rIFNα-2α during twice daily (0.5 to 36 million IU), 
once daily (1 to 54 million IU), or 3 times weekly (1 to 
136 million IU) dosing regimens up to 28 days of dosing. 
Multiple im doses of rIFNα-2α resulted in an accumulation 
of 2 to 4 times of the single dose serum concentrations.72
In a study of 12 males, the elimination half-life following 
sc or im injections of IFNα-2b (Intron® A) was approximately 
2 hours.73
IFN biomarkers and resistance
A number of surrogate markers have been investigated in 
order to deﬁ  ne the dose-response relationship of IFN-α. 
2,5 OAS, an enzyme induced by both IFN-α and IFN-γ, 
seems to play a role in IFN response. Increased levels of this 
enzyme were shown to correlate with decreased cell cycling 
in melanoma cell cultures treated with IFN.74 Other markers 
such as neopterin and β2 microglobulin were used to evaluate 
this hypothesis. Studies in melanoma75–77 provide conﬂ  icting 
data on the utility of neopterin levels in predicting response 
to immunotherapy. In aggregate, these markers may show 
laboratory conﬁ  rmation of stimulation of IFN, but do not 
provide consistent predictive information on the outcome 
of IFN therapy.
Another protein, Mx protein, associated with antiviral 
properties of IFN therapy, speciﬁ  cally type I and II IFN 
in vivo and in vitro, has been identiﬁ  ed.78 The Mx family, 
a subclass of high-molecular-weight GTPase, comprises 
MxA and MxB in humans and of Mx1 and Mx2 in mice.79 
MX family is encoded in human chromosome 21, which 
is synergic to mouse chromosome 16.80,81 MxA is induced 
selectively by type I IFNs and its expression requires STAT 
1 signaling.82 As a result, MxA protein is used as a surrogate 
marker for type I IFN activity in various experimental and 
clinical settings.83
Mx protein (Mx1) confers resistance to orthomyxoviruses 
and inhibits an inﬂ  uenza virus in ﬁ  shes, while (Mx2) inhibits 
rhabdoviruses and bunya viruses.84 The role of Mx as a 
predictive marker of antiproliferative effect of IFN-α in 
melanoma has been studied,85,86 also with conﬂ  icting results.
Yurkovetsky et al tried to evaluate speciﬁ  c predictive 
markers of clinical outcome and of IFNα-2b response in 
patients with high risk melanoma.87 Differences in serum 
concentrations in 29 cytokines, angiogenic and growth 
factors in melanoma patients before and after high dose 
IFNα-2b therapy and in healthy control groups were 
analysed.87 A statistically signiﬁ  cant increase in 15 proteins 
was observed in melanoma patients comparing to healthy 
individuals. IFN-α therapy decreased levels of angiogenic 
and growth factors (Vascular Endothelial Growth Factor 
VEGF, Epidermal Growth Factor EGF, Hepatocyte Growth 
Factor HGF), as it was noticed three months after the induc-
tion of therapy. However this did not seem to correlate 
with changes in recurrence free survival (RFS) among this 
population. It has also been shown that pre-treatment levels 
of pro-inﬂ  ammatory cytokines (IL-1a, IL-1b, IL-6, Tumor 
Necrosis Factor TNFa and Macrophage Inﬂ  ammatory Protein 
MIP-1a, MIP-1b) were higher in patients treated with IFN 
who had a RFS longer than 5 years compared to those with 
shorter RFS.
Furthermore Critchley-Thorne et al88 studied defects in 
T cell signaling (IFN signaling) in advanced melanoma patients, 
likely arising from their impaired response to IFN therapy. The 
reduced responses to IFNs could be involved in the suscepti-
bility of lymphocytes to spontaneous apoptosis in the cancer 
state, which is critical of tumor immune dysfunction. These 
effects were normalized in vitro by exposure to high dose 
IFN-α Finally it has recently been demonstrated that silencing 
the suppressor of cytokine signaling (SOCS) proteins on tumor 
cells, results in enhancement of the anti- proliferative effect 
of IFN-α and IFN-γ.89 SOCS proteins are negative regulators 
of IFN-signaling.90 It has been shown that increased levels of 
these proteins render cells resistant to IFN-α therapy.91
Further investigations are required to identify the mecha-
nisms of responsiveness to IFN therapy and to understand the 
possible mechanisms of resistance. Establishment of response 
markers would be helpful for the identiﬁ  cation of patients 
who would be more likely beneﬁ  ted from IFN-α therapy.
IFN-induced autoimmunity
The presence of autoantibodies or other clinical manifesta-
tions of autoimmunity after IFN treatment was shown to be 
associated with a prolongation in relapse-free survival.92Biologics: Targets & Therapy 2009:3 173
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Gogas et al92 investigated the appearance of auto-antibodies 
or other clinical manifestation of autoimmunity in a group 
of 200 patients in a sub-study of a larger randomized trial.92 
Patients were enrolled in two groups: in the ﬁ  rst they received 
IFNα-2b 15 MIU/m2 iv daily 5 days per week for 4 weeks 
while in the other they received the same induction dose 
followed by sc injections of 10 MIU IFNα-2b thrice weekly 
for an additional 48 weeks.
Induction of autoantibodies or clinical manifestations 
of autoimmunity were detected in 52 (26%) patients treated 
with IFNα-2b. Clinical manifestations of autoimmunity 
were more frequently detected in the group of patients that 
received treatment for 1 year. Antithyroid autoantibodies 
were most frequently observed (22% of the patients), while 
antinuclear antibodies were observed in 6% of the studying 
patients. Vitiligo was reported in 6% of the patients.
Detection of autoantibodies was associated with 
statistically signiﬁ  cant improvement in relapse-free survival 
and overall survival (OS). Median relapse-free survival was 
16 months among patients without autoimmunity (108 out of 
148) and was not reached among patients with autoimmunity 
(7 out of 52 had a relapse). Median relapse-free survival 
in patients without autoimmunity was 16 months (range 
0.3–74.3), whereas it was not reached during follow up in 
patients with autoimmunity (range 3.5–84.7 months).92
Nevertheless the role of autoimmunity, including 
vitiligo-like depigmentation, in patients with melanoma 
is not observed regularly as it occurs spontaneously or 
during chemotherapy. Spontaneous vitiligo was consid-
ered a favorable prognostic factor even before the advent 
of treatment with IL-2.93 As an example we present a 
patient with stage IV melanoma that developed vitiligo-like 
depigmentation during treatment with dacarbazine (DTIC) 
and pegylated IFN in the University Hospital of Zurich asso-
ciated with lasting complete remission (see Figure 2). We 
emphasize that the pattern of pigment loss is not identical 
to that of vitiligo (no acral and perioral involvement) and 
therefore should be coined vitiligo-coined depigmentation.
Figure 2 Complete remission associated with vitiligo-like depigmentation after therapy with dacarbazine and PegIFN-α.Biologics: Targets & Therapy 2009:3 174
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Pegylation
The need for a substance with broader therapeutic effect and 
more convenient pharmacokinetic proﬁ  le with less toxicity 
than conventional IFN led to pegylation of IFN-α.
The term pegylation describes the conjugation of a 
molecule with polyethylene-glycol (Peg), which is used to 
alter the physical and chemical proﬁ  le of the molecule.
Pegylation increases the stability and solubility of the drug, 
prolongs its activity, delays its clearance and reduces protein’s 
immunogenicity. As a result the administration frequency can 
be reduced; the pegylated form is injected once weekly, rather 
than 3 times per week for conventional IFN-α.
The FDA recently approved two PegIFN-α preparations 
for the treatment of chronic hepatitis (PegIFNα-2b was 
approved in January 2001 while PegIFNα-2α was approved 
in October 2002). Unfortunately, PegIFNs are not yet 
ofﬁ  cially approved for the treatment of melanoma.
PegIFNα-2b (Peg-Intron)
PegIFNα-2b presents as a derivate of recombinant IFNα-2b 
conjugated with PEG.94 The molecular weight of the PEG-
moiety is 12 kDa and it is attached to a linkage to histidine-34 
on IFNα-2b.95 The average molecular weight of PegIFNα-2b 
is 31 kDa.96
After sc administration of a single dose of PegIFNα-2b, 
mean absorption half-life was 4.6 hours.96 Glue et al studied 
the pharmacokinetic proﬁ  le of several dosages of PegIFNα-2b 
in patients with chronic hepatitis. Mean elimination half-life 
at ﬁ  rst week after administration of different dose schedules 
of PegIFNα-2b (0.35 μg/kg, 0.7 μg/kg, 1 μg/kg 1.4 μg/kg) 
varied from 40 to 58 hours in these patients. The mean peak 
serum concentrations (Cmax) in patients receiving the same 
dosage schedules occurred between 22 and 29 hours at week 1 
and between 22 and 19 hours at week 4 after dosing.97 This 
actually means that dose or duration of therapy did not cause 
much difference to absorption. An increase in bioavailability 
of Peg-Intron is described after multiple dosing.96 Time to 
steady state is reached by week 4.
Comparison of pharmacokinetics data in a randomized 
study with 1219 patients with chronic hepatits-C infection 
demonstrated no differences in efﬁ  cacy between patients 
treated with PegIFNα-2b in the dose of 0.5 μg/kg once 
weekly and those treated with sc injections of 3 MIU IFNα-2b 
thrice weekly. Patients were treated for 48 weeks and were 
followed up for an additional period of 24 weeks. Moreover 
this study showed that efﬁ  cacy of the combined virologic and 
biochemical response was increased with an increase in the 
dose of PegIFNα-2b compared with conventional IFN.98
PegIFNα-2α (Pegasys®)
PegIFNα-2α is recombinant IFNα-2α conjugated with 
a 40 kDa-branched Peg moiety and consists of major 
isomers.94 It is linked to the recombinant IFN via a stable 
amine to lysine bond.99 PegIFNα-2α has an approximate 
molecular weight of 60,000 Da.99
A dose of 180 μg of PegIFNα-2α in healthy volunteers 
produced Cmax of 14.2 μg/L, which was reached in a mean 
time (Tmax) of 78 hours.100 PegIFNα-2α is cleared both by 
the liver and the kidney in contrast to PegIFNα-2b which is 
cleared by the kidney. The elimination half-life is at about 
65 hours.99
Cmax and area under the curve (AUC) increased in a non-
linear dose-related manner after administration of different 
doses of Pegasys ranging from 90 to 270 μg.99 Maximal 
serum concentrations occur between 72 and 96 hours.99 
Steady state serum levels are reached within 5 and 8 weeks 
of once-weekly dosing.99
Drugs with a large volume of distribution require 
adjustment of a dose according to the prevailing body weight. 
As a result the 12 kD PegIFNα-2b is dosed on a weight-basis, 
whereas the 40 kD Peg IFNα-2α is given as a ﬂ  at dose.
Half-life, mean peak concentration time and clearing of 
conventional IFN and of PegIFNα-2b and PegIFNα-2α are 
compared in Table 1.
Efﬁ  cacy of PegIFN
PegIFN in the adjuvant setting
The most important factor determining survival in melanoma 
patients is disease stage. Measurement of tumor thickness 
with Breslow index and ulceration are used to determine the 
Table 1 Pharmacology of conventional IFN and two pegylated IFN preparations
Conventional IFN 12 kD PegIFN 40 kD PegIFN
Volume of distribution (L) 25–30 20–40 8
Half-life (h) 3–8  54 65
Time to serum peak (h) 7–12 20 80
Clearing Renal Renal Hepatic and renalBiologics: Targets & Therapy 2009:3 175
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prognosis of the primary tumor in stage I and II melanoma 
patients.101 For stage III melanoma patients four major criteria 
are used to determine outcome: number of metastatic lymph 
nodes, tumor burden (microscopic or macroscopic), the pres-
ence or absence of ulceration of the primary tumor, and the 
presence or absence of in transit or satellite metastases.101
Five-year survival for tumors with a thick Breslow index 
without involvement of lymph nodes ranges between 27% 
and 70%, decreasing to 10% to 19% in patients with positive 
lymph nodes.101 One-year survival in patients with distant 
metastases is 41% to 59%101 while 10-year survival rate is 
30% in patients with loco regional metastases in lymph nodes 
and less than 5% in those with distant metastases.102
With these features in mind, effective, adjuvant, postsur-
gical treatment following surgical interventions is urgently 
needed. Adjuvant chemotherapy and irradiation therapy 
failed to improve survival. Immunotherapy offers at least 
some promise.
A number of prospective randomized trials have been 
performed using adjuvant treatment with IFN in patients 
with cutaneous melanoma. Treatment with low, intermediate 
and high doses of IFN-α after resection of primary tumor 
has improved RFS, but without conﬁ  rmed signiﬁ  cant effects 
on OS.103–105
The ﬁ  rst trial that showed a positive effect on OS was 
ECOG 1684.106 287 patients were enrolled to receive a high 
dose of IFN-α for 1 year versus observation. Twenty-ﬁ  ve 
percent of the patients had to be withdrawn due to severe 
adverse effects. Five-year disease-free survival (DFS) was 
37% versus 26% and OS was 46% versus 37%.106 On this 
basis, high-dose adjuvant IFN-α won FDA approval. A meta-
analysis of several high dose IFN trials showed no statistically 
signiﬁ  cant effect on OS.104 It was then proposed that IFN 
might exert its best effect in long-term therapy.105 Clariﬁ  cation 
of the role of high dose IFN would need a large prospective 
trial comparing it with long-term low dose IFN therapy.
Since PegIFN-α is suitable for long-term therapy, the 
European Organisation for Research and treatment of Cancer 
(EORTC) has designed a large prospective randomized trial 
to investigate the potent positive effect of PegIFNα-2b in 
the adjuvant setting in patients with stage III melanoma. 
The largest trial ever conducted with PegIFN (EORTC 
18991 study) was recently published.107 1256 patients from 
99 centers in 17 countries with resected stage III melanoma 
were randomized to receive observation or PegIFN-α.107 
Randomization was stratiﬁ  ed for microscopic (N1) versus 
macroscopic (N2) nodal involvement, number of positive 
nodes, ulceration and tumor thickness. RFS (primary 
endpoint), distant-metastases-free survival (DMFS) and OS 
were analyzed for the intent-to-treat population.
The IFN group received an induction IFN dose of weekly 
dose of 6 μg/kg for the ﬁ  rst 8 weeks and then the dose was 
reduced to 3 μg/kg per week for 5 years.107
At 3.8 years of median follow up, RFS was signiﬁ  cantly 
reduced by 18% in the PegIFNα-2b arm compared with 
observation; the 4-year RFS rate was 45.6% versus 38.9%. 
DMFS was improved but nonsigniﬁ  cantly (p = 0.11). OS 
was unchanged in the two groups. In stage III-N1a (micro 
metastases detected in the sentinel node) both RFS (hazard 
ratio [HR] 0.72, 57.7% versus 45.4%, p = 0.01) and DMFS 
(HR 0.73, 60.5% versus 52.6%, p = 0.01) were prolonged in 
the PegIFNα-2b arm, whereas in stage III-N1b (macroscopic 
metastases) there was no beneﬁ  t.107
This trial showed that a prolonged adjuvant treatment 
with IFN-α improved the RFS period and DMFS in a sub-
group of patients with low tumor burden. According to these 
results, further search for predictive clinical or biological 
markers that can identify patients who are more likely to 
beneﬁ  t from IFN treatment is encouraged.107
Safety and efﬁ  cacy of adjuvant treatment with PegIFNα-2α 
100 μg sc weekly for 36 months versus conventional 3 MIU 
IFNα-2α thrice weekly for 18 months is investigated in 
another European, multicenter, prospective trial performed 
by the Dermatologic Cooperative Oncology Group (EADO). 
880 patients with melanoma stage IIA-IIIB are randomized 
to receive adjuvant treatment after surgical excision. Inclu-
sion criteria were tumor thickness 1.5 mm and absence of 
regional nodal macro-metastases as assessed either by clinical 
examination or if, sentinel lymph node dissection (SLNB) 
or elective node dissection (ELND) are performed, by the 
absence of macroscopic evidence of disease. Patients with 
evidence of nodal macro-metastasis by SNLB or ELND are 
eligible. The primary endpoint of the study is 5-year DFS.
The results are pending.
Another randomized European trial is investigating 
PegIFNα-2α in a dose of 180 μg per week versus 
observation.
PegIFN in palliative disease 
(stage IV melanoma)
As noted to above, stage IV malignant melanoma remains a 
rapidly fatal disease despite treatment.102 Surgical excision, 
systemic chemotherapy, irradiation, immunotherapy or 
combinations of these are offered to patients without any 
proven evidence for any effect on survival. Therefore 
participation in clinical trials is recommended.Biologics: Targets & Therapy 2009:3 176
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PegIFN as monotherapy 
in stage IV melanoma
The use of PegIFN as monotherapy was evaluated in a 
study reporting a multicenter, randomized-dose comparison 
phase II trial.108 This trial evaluated the efﬁ  cacy of PegIFN 
monotherapy in patients with stage IV metastatic melanoma. 
150 patients were randomized to receive PegIFN in three 
different dose-schedules. One group received 180 μg once 
a week; other groups received 360 μg or 450 μg weekly. 
The treatment phase was 24 weeks, followed by an 8-week 
follow up time. Patients with previous chemotherapy or 
immunotherapy with IL-2 for stage IV melanoma were 
excluded. Approximately 20% of the patients had previously 
received IFN as adjuvant therapy.108 Tumor responses were 
conﬁ  rmed by an independent radiology review board. The 
overall response rate (complete or partial response) was 
6%, 8% and 12% for the three groups, respectively. The 
difference between the dose groups was not statistically 
signiﬁ  cant. In addition, there was a tendency that low-dose 
treated patients presented a higher tumor burden. There was 
also no signiﬁ  cant difference between stable and progressive 
disease among three groups.108
Unfortunately this trial does not clarify whether there is a 
true dose-response relationship with PegIFN in patients with 
metastatic melanoma due to the small number of the patients 
recruited in this study. The overall response rate in this trial 
is very similar to the response rate in a comparable patient 
population treated with DTIC monochemotherapy.109,110 It is 
challenging to argue that the targeted population includes a 
minority of patients who are able to respond to a therapeutic 
intervention, independent of its nature.
PegIFN in combination 
with chemotherapy
The combination of PegIFN and chemotherapy has been 
evaluated in different types of cancers.111,112 Several studies 
have been performed to evaluate the efﬁ  cacy of combined 
chemotherapy and immunotherapy in patients with 
melanoma.
A randomized trial performed by the German Dermatologic 
Cooperative Oncology group (DECOG) investigated 
temozolomide (TMZ) alone in a daily dose of 200 mg/m2; 
(day 1–5 every 28 days) or in combination with sc IFN-α 
(5 MIU/m2; day 1, 3, 5, every week).113 282 patients were 
eligible for intent-to-treat analysis, 271 patients were treated 
per protocol. In the TMZ plus IFN-α arm, 33 out of 137 
patients (24.1%) responded to therapy (partial or complete 
response) whereas in monotherapy arm in 18 of 134 patients 
(13.4%) a response was evident. Thus the response rate 
was signiﬁ  cant higher in the combination arm (p = 0.036). 
Median survival time was 8.4 months for patients treated with 
TMZ and 9.7 months for those treated with the combination 
(p = 0.16). Dose modiﬁ  cations and interval prolongations 
due to hematologic toxicity were signiﬁ  cantly more frequent 
in the combination group (p = 0.001).113 These results were 
indicators for further investigation.
Hwu et al enrolled 35 patients with stage IV melanoma 
to receive 0.5 μg/kg weekly PegIFNα-2b plus TMZ 
75 mg/m2 daily for 6 days per week with a 2-week break 
between the cycles.114 Patients with brain metastases, 
pregnant or lactating patients or patients with evidence of 
other tumor except nonmelanoma skin or in situ cervical 
cancer were excluded. Median number of metastatic sites 
was 3 and the most common sites of metastasis were soft 
tissue, lymph nodes and lungs, indicating a selection of 
patients with a relatively favorable prognosis. No patient 
had received previous chemotherapy. Thirty-one percent 
of the patients experienced objective response (complete 
and partial) while 6% had stable disease (SD) which is 
a surprising ratio. Sixty-three percent of the patients had 
progressive disease. At the time of the last follow up 27 out 
of 35 patients had died of their disease. The median survival 
for the responders (both complete response [CR] and partial 
response [PR]) was 20.2 months and the median survival 
time for nonresponders was 6.9 months.114 This study 
reported a very high response rate which was not conﬁ  rmed 
by independent radiology assessment. The survival reported 
is longer than with dacarbazine or TMZ alone115 but again 
the results need conﬁ  rmation in a randomized trial.
No grade IV hematological adverse effects (AEs) were 
experienced in the study. Other grade IV adverse effects 
were central nervous system hemorrhage and thrombosis/
pulmonary embolism reported in one case (3%). This seemed 
to be neither PegIFN dose-related nor disease-dependent 
(hemorrhagic stroke in the absence of thrombocytopenia or 
clinical evidence of brain metastasis).
The efﬁ  cacy of PegIFNα-2b combined with monoche-
motherapy was investigated in another study performed by 
Spieth et al.116 The study was designed based on previously 
published results from DECOG using combination of immu-
notherapy and chemotherapy.113 124 patients with metastatic 
melanoma were included in the study. The patients received 
oral TMZ 200 mg/m2 for 5 days every 28 days. In addition 
sc injections of 100 μg PegIFNα-2b were administered once 
a week.116 Patients with brain metastases were excluded as Biologics: Targets & Therapy 2009:3 177
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were patients with severe cardiac, pulmonary, psychiatric or 
metabolic diseases. No patient had received prior systemic 
chemotherapy. In all patients, 18.1% showed complete 
or partial response, 25% achieved stable disease, while in 
56.9% of the patients the disease was progressive.116 Median 
overall survival (MOS) in responders was 15.2 months and 
in nonresponders was 8.6 months. Fifty out of 116 patients 
had an adjustment in the treatment due to adverse effects.116 
Grade III and grade IV toxicities included leukopenia 
(23.3%) and thrombocytopenia (41.4%), which is more than 
observed with TMZ alone. One patient was diagnosed with 
sarcoidosis shortly after initiation of treatment.
Twenty-eight patients with stage IV malignant melanoma 
without brain metastases were enrolled in a multicenter phase II 
study.117 Patients were treated with 850 mg/m2 DTIC every 
3 weeks combined with 180 μg PegIFNα-2α weekly. Only 
50% of the patients participating in the study had received 
previous adjuvant therapy with IFN-α. This study was initiated 
to evaluate the efﬁ  cacy and tolerability of the combination. 
Primary endpoint was objective response (OR).
Two patients (8%) achieved CR which lasted for more 
than 480 days and for 746 days respectively. Four patients 
(16%) had a PR and another patient developed SD, which 
means that 24% of the patients achieved PR or CR. Median 
progression-free survival was 56 days, median duration of 
response was 236 days and OS time was 403 days.117 Of 
interest is the fact that 6 out of 7 patients who showed CR 
or PR or developed SD had not received IFN adjuvant treat-
ment in the past or progressed to stage IV melanoma during 
IFN treatment.
One patient had to discontinue the treatment due to serious 
AE (dizziness). The patient discontinued the treatment after 
showing complete response of her lung metastases.
This combination was well tolerated. Because of the 
design, the impact on survival cannot be assessed. The 
long-term remission observed in IFN-naïve patients suggests 
that combination of chemotherapy with IFN might be 
especially promising in this population.
Vaishampayan et al aimed to evaluate the efficacy 
of PegIFNα-2b combined with thalidomide in patients 
with stage IV metastatic melanoma. Eighteen patients 
were enrolled to receive 0.5 μg/kg sc daily plus 250 
mg thalidomide orally.118 Nine out of 18 patients had 
received previous adjuvant treatment, while 16 out of 
18 patients had also received previous chemotherapy.118 
No objective responses were noted; 3 patients demon-
strated disease stabilization for a rate of 3/18 = 17% (90% 
conﬁ  dence interval [CI] 0.06–0.35).118 The stable disease 
durations were 4, 5 and 15 months. Median survival was 7.2 
months, with 90% CI, 4.1–13.6 months.118 The 6-month and 
1-year OS rates were 58% and 35%, respectively. Grade IV 
toxicity was hematologic toxicity (anemia and thrombocy-
topenia) which was experienced in 3 of 18 (16.6%) patients. 
The combination was well tolerated, though without clinical 
efﬁ  cacy.
Side effects of PegIFNs
IFN-α therapy is associated with a wide spectrum of side 
effects that present in various severities depending on dose 
and individual susceptibility. Unfortunately, there are no 
clinical or laboratory studies predicting individual toler-
ability. The FDA deﬁ  nes a serious AE to be life threatening 
or to cause death, or initial or prolonged hospitalization, or 
when one AE causes signiﬁ  cant, persistent, or permanent 
disability, impairment, or disruption in the patient’s body 
structure, physical activities, or quality of life.119 An AE 
is also considered serious when it requires intervention to 
prevent permanent damage.119
Initially, the patients who are candidates for IFN therapy 
need detailed information about the nature of the drug. 
Understanding IFN as a biologic medication and not another 
cytostatic drug contributes to a better acceptance of the most 
prominent ﬂ  u-like side symptoms. It is also helpful to encour-
age variations in the treatment schedule that interfere as little 
as possible with the daily activity of the individual.
Several interventions to alleviate the constitutional 
side effects such as dose decrement or cessation of 
treatment interruptions are necessary. Premedication 
with acetaminophen, ibuprofen or other non-steroidal 
anti-inﬂ  ammatory drugs (NSAIDs) and/or antiemetics is 
believed to reduce the severity of ﬂ  u-like symptoms.120 
IFN administration at bedtime can also help.121 Patients 
are also advised to avoid hepatotoxic agents and large 
quantities of alcohol while on treatment with IFN. Regular 
hematological and biochemical tests (including thyroid 
antibodies) need to be drawn at baseline, monthly for the 
ﬁ  rst 3 months and afterwards every 3 months when patients 
are treated with PegIFN-α.96,99
Side effects of PegIFNα-2b
In Table 2 we compare the most commonly reported adverse 
effects related to IFNα-2b and PegIFNα-2b therapy.
There are no signiﬁ  cant differences between the incidence 
of AEs experienced by hepatitis patients comparing low 
doses of PegIFNα-2b (1 μg/kg) and conventional IFNα-2b 
at a dose of 3 MIU (see Table 2).Biologics: Targets & Therapy 2009:3 178
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In the population of melanoma patients treated in the 
EORTC 18991 study, 31% treated with PegIFNα-2b 
discontinued treatment due to AEs.107 Flu-like symptoms and 
depression were more severe in the PegIFN group compared 
to observation (see Table 2). Grade I–IV AEs most often 
associated with drug discontinuation were fatigue (25%), 
depression (16%), anorexia (15%), abnormal liver function 
tests (13%), myalgias (13%), headache (12%), nausea (12%) 
and pyrexia (11%).107 The incidence of these symptoms was 
higher early in treatment and did not seem to increase with 
longer treatment duration.107
Side effects of PegIFNα-2α
In Table 3 we compare the most commonly reported AEs 
related to IFNα-2α and PegIFNα-2α therapy.
As with PegIFNα-2b and IFNα-2b, there are no 
significant differences in incidence of AEs comparing 
IFNα-2α and PegIFNα-2b at the doses of 3 MIU and 180 μg 
respectively.
As it can be seen from Table 3 in the study performed 
by Dummer et al in melanoma patients, there were also no 
meaningful differences in AEs recorded for the three doses 
of PegIFN. Reductions or withholding of doses due to 
AEs or laboratory abnormalities were documented in 23% 
(n = 11), 51% (n = 27) and 41% (n = 20) of patients treated 
with PegIFNα-2α at doses of 180, 360 and 450 μg, respec-
tively.108 In all dose groups, most dose adjustments occurred 
in the ﬁ  rst 3 months.
According to this trial, fatigue and ﬂ  u-like symptoms 
were the most frequently reported AEs, with 14% of patients 
in the 450 μg group reporting severe fatigue. Ninety-six 
percent of patients in the 180 μg group and 100% in the 
360 μg and 450 μg groups experienced at least one AE but 
88% of these were mild or moderate.108
There was a clear difference in the AE-based discon-
tinuation rate between the 180 μg weekly versus the 360 μg 
group. However, there was no obvious difference between 
the 360 μg and 450 μg/weekly groups.108
Other rare toxicities related to PegIFN therapy include ret-
inopathy, retinal hemorrhage, optic neuritis and papilledema. 
Bone marrow toxicity, alopecia and injection side reactions 
are uncommon AEs.96,99 PegIFN treatment is also related to 
exacerbation or development of autoimmune diseases such as 
thyroiditis, adrenal dysfunction, Raynaud phenomenon, pso-
riasis, autoimmune hepatitis, rheumatoid arthritis and lupus 
erythematosus. Sarcoidosis, interstitial lung disease, Stevens-
Johnson Syndrome, erythema multiform and Lyell Syndrome 
are very rare AEs related to PegIFN treatment.122
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Summary and conclusions
PegIFNs have been successfully introduced into melanoma 
therapy. Their pharmacologic proﬁ  le allows a comfortable once 
weekly injection schedules. In the adjuvant setting PegIFNα-2b 
is the preferred medication for long-term therapy that increases 
distant metastases-free survival in patients with microscopic 
node involvement. Especially young patients with no signiﬁ  cant 
co-morbidities are candidates for this approach. Side effects 
of PegIFNs are substantial. Therefore, there is a strong need 
for a detailed discussion of the pros and cons with the patient 
before therapy. The most common adverse effects include 
constitutional, neuropsychiatric, hematologic and hepatic 
toxicity. Careful monitoring during treatment is necessary. 
Side effects are dose-dependent and they affect patient quality 
of life. An ongoing dialogue must occur between the patient 
and physician to ensure that all aspects of toxicity related to 
PegIFN are anticipated and treated. Autoimmunity phenomena 
induced by IFN treatment may be important surrogate markers 
for successful antitumor effect. However additional predictive 
markers are necessary to identify the melanoma population 
who will beneﬁ  t most from this immunotherapy.
Large multicenter trials in specialized centers are encour-
aged to address this issue by the collection of biological 
samples in large bio-banks.
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